Cardinal Health Nears 52-Week High as Earnings and Institutional Buys Drive Optimism Volume Ranks 423rd at 300M

Market Snapshot

Cardinal Health (CAH) closed with a modest gain of 0.17% on February 23, 2026, as its shares traded with a volume of $300 million, ranking 423rd in trading activity for the day. The stock’s performance aligns with its recent trajectory, hovering near its 52-week high of $230.81, though trading below its 50-day moving average of $211.38. The company’s market capitalization stands at $52.76 billion, with a price-to-earnings ratio of 32.26 and a beta of 0.64, reflecting relatively low volatility compared to the broader market.

Key Drivers

Cardinal Health’s recent earnings report and institutional investment activity emerged as pivotal catalysts for its stock performance. The company reported fourth-quarter earnings of $2.63 per share, surpassing the $2.31 consensus estimate and marking a 36.3% year-over-year increase in earnings. Revenue surged to $65.63 billion, an 18.8% rise compared to the prior-year quarter, driven by strong demand in acute care services and pharmaceutical distribution. This outperformance, combined with a 0.68% net margin, signaled operational resilience despite a negative return on equity of -92.50%, which analysts attribute to restructuring costs and inventory management challenges.

The company also announced a quarterly dividend of $0.5107 per share, annualizing to $2.04 and yielding 0.9%. The payout, scheduled for April 15, reflects a 29.35% payout ratio, suggesting sustainability while balancing reinvestment needs. Analysts highlighted the dividend as a confidence booster for income-focused investors, particularly given the company’s stable cash flow generation.

Institutional investor activity further underpinned the stock’s strength. Tredje AP fonden increased its stake by 30.3% in the third quarter, while Vanguard Group Inc. added 0.8% of its holdings, now valued at $4.84 billion. Norges Bank entered the second quarter with a $584 million position, and Invesco Ltd. boosted its holdings by 7.3%. Collectively, institutional investors own 87.17% of the company’s shares, underscoring confidence in its long-term strategic positioning.

Analyst sentiment reinforced the stock’s appeal. UBS Group upgraded its price target to $260, TD Cowen raised its estimate to $251, and Leerink Partners set a $268 target with an “outperform” rating. Despite Wall Street Zen’s downgrade from “strong-buy” to “buy,” the consensus remains a “Moderate Buy” with a $244.20 price target. These ratings reflect optimism about Cardinal Health’s ability to capitalize on healthcare sector tailwinds, including rising demand for medical technology and supply chain optimization.

However, the stock’s valuation metrics present a nuanced picture. A PEG ratio of 1.45 suggests it trades at a premium relative to earnings growth expectations, while its beta of 0.64 indicates lower volatility than the market. Analysts caution that execution risks, such as margin pressures and regulatory challenges, could temper long-term gains. Nevertheless, the combination of earnings momentum, dividend stability, and institutional backing positions Cardinal Health as a defensive play in a sector poised for growth.